P687Is sacubitril/valsartan useful in patients with cancer and heart failure? Data from HF-COH Spanish multicenter registry
Ana Martín‐Garcia(Complejo Hospitalario de Salamanca), Teresa López‐Fernández(Hospital Universitario La Paz), Pedro Moliner(Bellvitge University Hospital), Amparo Martínez‐Monzonís(Instituto de Salud Carlos III), C Asla(Hospital Universitario La Paz), Marinela Chaparro(Hospital Universitario Virgen Macarena), Cristina Mitroi(Hospital Universitario Puerta de Hierro Majadahonda), Milena Antúnez Ballesteros, Francisco Gual‐Capllonch(Hospital Universitari Germans Trias i Pujol), Clara Sánchez-Pablo(Centro de Investigación en Red en Enfermedades Cardiovasculares), J. López Sendón(Hospital Universitario La Paz), Antonio Castro(University of Almería), Pedro L. Sánchez(Instituto de Investigación Biomédica de Salamanca)
Cited by 0
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
|European Heart Journal|2016|2.5k
2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice Guidelines
|European Journal of Heart Failure|2016|1.8k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589